Canadian company Sandoz is set to launch the very first generic semaglutide in 2026, making this costly treatment more accessible, possibly raising other issues.
PHAC says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.
The European Pharmacovigilance Risk Assessment Committee reviewed reported cases and post-marketing safety data to evaluate the risks of PRES and RCVS with pseudoephedrine-containing medicines.
